1.Center for Disease Control and Prevention. Vital signs: teen pregnancy – United States, 1991–2009. Morb Mortal Wkly Rep. 2011; 60, 414–420.
2.Felice, ME, Feinstein, RA, Fisher, MM, et al. . Adolescent pregnancy – current trends and issues: 1998 American Academy of Pediatrics Committee on Adolescence, 1998–1999. Pediatrics. 1999; 103, 516–520.
3.Black, AJ, Topping, J, Durham, B, Farquharson, RG, Fraser, WD. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res. 2000; 15, 557–563.
4.Naylor, KE, Iqbal, P, Fledelius, C, Fraser, RB, Eastell, R. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res. 2000; 15, 129–137.
5.Cross, NA, Hillman, LS, Allen, SH, Krause, GF, Vieira, NE. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr. 1995; 61, 514–523.
6.Kovacs, CS. Calcium and bone metabolism in pregnancy and lactation. J Clin Endocrinol Metab. 2001; 86, 2344–2348.
7.Kolthoff, N, Eiken, P, Kristensen, B, Nielsen, SP. Bone mineral changes during pregnancy and lactation: a longitudinal cohort study. Clin Sci (Lond). 1998; 94, 405–412.
8.Sowers, M, Wallace, RB, Lemke, JH. Correlates of forearm bone mass among women during maximal bone mineralization. Prev Med. 1985; 14, 585–596.
9.Sowers, MF, Scholl, T, Harris, L, Jannausch, M. Bone loss in adolescent and adult pregnant women. Obstet Gynecol. 2000; 96, 189–193.
10.Simonet, WS, Lacey, DL, Dunstan, CR, et al. . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89, 309–319.
11.Hofbauer, LC, Heufelder, AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001; 79, 243–253.
12.Hong, JS, Santolaya-Forgas, J, Romero, R, et al. . Maternal plasma osteoprotegerin concentration in normal pregnancy. Am J Obstet Gynecol. 2005; 193, 1011–1015.
13.Naylor, KE, Rogers, A, Fraser, RB, et al. . Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab. 2003; 88, 5361–5365.
14.Uemura, H, Yasui, T, Kiyokawa, M, et al. . Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. J Endocrinol. 2002; 174, 353–359.
15.Barker, DJ. The origins of the developmental origins theory. J Intern Med. 2007; 261, 412–417.
16.Gluckman, PD, Hanson, MA, Cooper, C, Thornburg, KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008; 359, 61–73.
17.Cooper, C, Westlake, S, Harvey, N, et al. . Review: developmental origins of osteoporotic fracture. Osteoporos Int. 2006; 17, 337–347.
18.Schlussel, MM, Dos, SV, Kac, G. Birth weight and adult bone mass: a systematic literature review. Osteoporos Int. 2010; 21, 1981–1991.
19.Kramer, MS, Platt, RW, Wen, SW, et al. . A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001; 108, E35–E42.
20.Gundberg, CM, Cole, DE, Lian, JB, Reade, TM, Gallop, PM. Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab. 1983; 56, 1063–1067.
21.Andreasyan, K, Ponsonby, AL, Dwyer, T, et al. . Higher maternal dietary protein intake in late pregnancy is associated with a lower infant ponderal index at birth. Eur J Clin Nutr. 2007; 61, 498–508.
22.Lonergan, M, Aponso, D, Marvin, KW, et al. . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. J Clin Endocrinol Metab. 2003; 88, 3835–3844.
23.Briana, DD, Boutsikou, M, Baka, S, et al. . Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction. Neonatology. 2009; 96, 132–136.
24.Dimitri, P, Wales, JK, Bishop, N. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone. 2011; 48, 189–196.
25.Specker, B. Nutrition influences bone development from infancy through toddler years. J Nutr. 2004; 134, 691S–695S.
26.Namgung, R, Tsang, RC. Factors affecting newborn bone mineral content: in utero effects on newborn bone mineralization. Proc Nutr Soc. 2000; 59, 55–63.
27.Raman, L, Rajalakshmi, K, Krishnamachari, KA, Sastry, JG. Effect of calcium supplementation to undernourished mothers during pregnancy on the bone density of the bone density of the neonates. Am J Clin Nutr. 1978; 31, 466–469.
28.Viljakainen, HT, Korhonen, T, Hytinantti, T, et al. . Maternal vitamin D status affects bone growth in early childhood – a prospective cohort study. Osteoporos Int. 2011; 22, 883–891.
29.Javaid, MK, Crozier, SR, Harvey, NC, et al. . Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet. 2006; 367, 36–43.
30.Dennison, EM, Arden, NK, Keen, RW, et al. . Birthweight, vitamin D receptor genotype and the programming of osteoporosis. Paediatr Perinat Epidemiol. 2001; 15, 211–219.
31.Antoniades, L, MacGregor, AJ, Andrew, T, Spector, TD. Association of birth weight with osteoporosis and osteoarthritis in adult twins. Rheumatology (Oxford). 2003; 42, 791–796.
32.Dai, Y, Shen, L. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl). 2007; 120, 2017–2021.
33.Jiang, LS, Zhang, ZM, Jiang, SD, Chen, WH, Dai, LY. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis. J Bone Miner Res. 2008; 23, 475–483.
34.Ohwada, R, Hotta, M, Sato, K, Shibasaki, T, Takano, K. The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa. Endocr J. 2007; 54, 953–959.
35.Hofbauer, LC, Khosla, S, Dunstan, CR, et al. . Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999; 140, 4367–4370.
36.Li, Q, Yu, K, Tian, X, et al. . 17beta-estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro. Leuk Res. 2009; 33, 1266–1271.
37.Looker, AC, IIIMelton, LJ, Harris, T, et al. . Age, gender, and race/ethnic differences in total body and subregional bone density. Osteoporos Int. 2009; 20, 1141–1149.
38.Emery, JG, McDonnell, P, Burke, MB, et al. . Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273, 14363–14367.
39.Vitovski, S, Phillips, JS, Sayers, J, Croucher, PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 2007; 282, 31601–31609.
40.Collin-Osdoby, P, Rothe, L, Anderson, F, et al. . Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001; 276, 20659–20672.
41.Corallini, F, Celeghini, C, Rimondi, E, et al. . TRAIL down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol. 2011; 226, 2279–2286.
42.Anum, EA, Springel, EH, Shriver, MD, IIIStrauss, JF. Genetic contributions to disparities in preterm birth. Pediatr Res. 2009; 65, 1–9.
43.Velez, DR, Fortunato, SJ, Morgan, N, et al. . Patterns of cytokine profiles differ with pregnancy outcome and ethnicity. Hum Reprod. 2008; 23, 1902–1909.